The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The of an antibody specificity in method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.

This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.

Provided are methods directed to enriching nucleic acids in a biological sample. These methods, in some embodiments can discriminately enrich the abundance of low-copy nucleic acids relative to higher-copy nucleic acids. In some embodiments, the methods provided can enrich a low-copy number mutant allele associated with a disease state, thus allowing early detection and optimized treatment. In other embodiments, the methods can be used for detection of particular molecules, such as antigens, in a sample.

The present invention is directed to intelligent algorithms, methodologies and computer-implemented methodologies for biophysical and biochemical cellular monitoring and quantification enabling enhanced performance and objective analysis of advanced infectivity assays including neutralization assays and adventitious agent testing using fluidic and optical force-based measurements.

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

Provided herein is a human monoclonal antibody 8D6 against hepatitis C virus (HCV) infection. The antibody binds to the E2 subunit of HCV capsid protein, and can prevent HCV from infecting susceptible host cells. By using the antibody variable region gene or the complementary determining region (CDR) gene, different forms of genetic engineering antibodies have been transformed and produced in any expression system of the prokaryotic and eukaryotic cells as therapeutics to prevent or treat HCV infection.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

A lateral flow assay cassette including a vertical swab holder is provided herein. Also provided are kits including the lateral flow assay cassette and methods of detecting an analyte using the lateral flow assay cassette.